Bei Jing Shang Bao·2025-08-22 14:04Core Viewpoint - Rongchang Biologics (688331) reported a significant increase in revenue and a reduction in net loss for the first half of the year, indicating positive operational trends and improved financial health [1] Financial Performance - The company's revenue for the first half of the year was approximately 1.098 billion yuan, representing a year-on-year increase of 48.02% [1] - The net profit attributable to shareholders was approximately -450 million yuan, showing a reduction in loss compared to the previous year [1] Key Drivers - The reduction in net loss was primarily attributed to the continuous increase in sales of Tai Tasi Pu and Vidi Si Tuo Kan, which contributed to higher product gross margins [1] - The decrease in sales expense ratio and reduced research and development investment also played a significant role in improving the financial performance [1]